773.282.9845
3401 N. Central Avenue Chicago, IL 60634

TREATMENT-RESISTANT DEPRESSION STUDIES

TREATMENT-RESISTANT DEPRESSION 

RESEARCH STUDIES

What is this study investigating?

The purpose of this study is to investigate the long-term efficacy and safety of Rexulti® (Brexpiprazole) used as an adjunct-treatment with an oral antidepressant, compared to placebo used in conjunction with an oral antidepressant.

What is Rexulti®? Rexulti® is an FDA-approved oral medication designed to be taken in tandem with a traditional oral antidepressant medication. This medication was designed to target symptoms of depression that traditional antidepressants do not adequately treat.

Overview: This is a 47-55-week long clinical trial that entails once a week in-office visits for the first 20-weeks, which will then drop down to monthly and once every 3-month visits. Some visits may be done remotely.

You May Qualify If:
–        You are 18 to 65 years of age
–        You are currently on an oral antidepressant medication and have tried at least one other antidepressant in the past
–        You are still experiencing symptoms of depression

Qualified candidates may be compensated up to $1,900. Free transportation assistance may be provided to those who enroll.

Contact Us